Abstract
The potential predictive value of soluble checkpoint molecules for immune checkpoint inhibitor has been shown in several malignancies including non-small cell lung cancer and renal cell carcinoma, but not in gastric cancer. We thus assessed the association of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1) and soluble Cytotoxic T-Lymphocyte-Associated protein 4 (sCTLA-4) with efficacy measures including survival in advanced gastric cancer patients treated with nivolumab monotherapy using blood samples collected from a prospective observational and translational study (DELIVER [JACCRO-GC08] trial).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
